Benefits
Skin Protection Against UV Damage
PL has antioxidant properties that help reduce UV-induced oxidative stress in skin. Studies report it can raise the skin's threshold for a visible UV reaction (increasing the minimal erythemal dose) and help protect skin cells and DNA from UV-related damage. It has been studied for supporting skin against photoaging changes such as wrinkles and uneven pigmentation, and for preserving Langerhans cells and reducing inflammation after UV exposure.
Anti-Inflammatory Effects
PL inhibits pro-inflammatory molecules like TNF-alpha and reduces oxidative stress, which may support calmer, more resilient skin. It has been studied in dermatology research for inflammatory and photosensitivity skin conditions, but as an oral supplement it is a complement to, not a substitute for, medical care.
Photodermatosis Management
For conditions like polymorphous light eruption (PMLE), PL reduces symptoms such as itching and rashes triggered by sun exposure. It’s been shown to allow longer sun exposure without reactions in sensitive individuals.
Antioxidant Support
PL contains phenolic compounds (e.g., ferulic acid, caffeic acid) that scavenge free radicals, protecting cells from oxidative stress. This supports overall skin health and may have broader anti-aging benefits.
Immune Modulation
PL may enhance immune function by protecting immune cells and reducing systemic inflammation, potentially aiding autoimmune skin disorders.
DNA Protection Support
Preliminary research suggests PL's antioxidant and DNA-protective effects may help shield skin cells from UV-induced DNA damage. This is an area of early study and more research is needed.
Mechanism of action
Antioxidant Activity
PL contains phenolic compounds (e.g., ferulic acid, caffeic acid, chlorogenic acid) that act as potent antioxidants. These neutralize reactive oxygen species (ROS) generated by UV radiation or other stressors, preventing oxidative damage to DNA, lipids, and proteins in skin cells. This reduces UV-induced cellular apoptosis and photoaging.
Photoprotection
Reducing cyclobutane pyrimidine dimers (CPDs), which are DNA lesions caused by UV exposure, thereby lowering the burden of UV-induced DNA mutations. Preserving Langerhans cells (immune cells in the skin) critical for immune surveillance, which are typically depleted by UV radiation. Decreasing erythema (redness) by limiting UV-induced vasodilation and inflammation.
Anti-Inflammatory Effects
PL suppresses pro-inflammatory cytokines (e.g., TNF-alpha, IL-6) and reduces the expression of inflammatory mediators like cyclooxygenase-2 (COX-2). This helps mitigate UV- and inflammation-related skin stress.
Immune Modulation
By protecting immune cells and regulating inflammatory pathways, PL supports immune homeostasis, potentially benefiting autoimmune skin disorders (e.g., vitiligo, polymorphous light eruption).
Matrix Protection
PL inhibits matrix metalloproteinases (MMPs), enzymes that degrade collagen and elastin in the skin due to UV exposure. This helps maintain skin structure and prevents photoaging signs like wrinkles.
DNA Repair Support
PL enhances DNA repair mechanisms by promoting the activity of nucleotide excision repair pathways, which correct UV-induced DNA damage.
Clinical trials
Randomized, double-blind, placebo-controlled trial in 40 healthy adults examining safety and efficacy of oral PLE supplementation.
40 healthy adults.
PLE was safe and produced modest photoprotective effects vs placebo. Generally well-tolerated.
Clinical trial in 22 subjects (Fitzpatrick skin types I-III) irradiated with visible light, UVA1, and UVB before and after oral PLE supplementation.
22 fair-skinned adults.
PLE modestly increased minimal erythemal dose (MED) — providing photoprotective effect. Critical caveat: not a sunscreen replacement — modest oral photoprotection that should be adjunctive to topical SPF. Topical sunscreen remains the foundation of UV protection.
Open, uncontrolled bicenter study in 35 patients with long-standing polymorphic light eruption treated with oral hydrophilic Polypodium leucotomos extract before photoprovocation (Tanew et al., J Am Acad Dermatol 2012). NOTE: this entry cites the same PMID (21696853) as the following trial and should be consolidated with it.
35 PLE patients.
After oral PLE, 30% of patients became unresponsive to UVA photoprovocation and the remainder required significantly more UV exposures to trigger the eruption. This was an open, uncontrolled study with no placebo group. PMLE is a photosensitivity disorder requiring dermatologic care.
Open, uncontrolled bicenter study in 35 patients with long-standing polymorphic light eruption receiving oral hydrophilic Polypodium leucotomos extract before photoprovocation (Tanew et al., J Am Acad Dermatol 2012).
35 PLE patients.
After oral PLE, 30% of patients became unresponsive to UVA photoprovocation and the remainder needed significantly more UV exposures to provoke PLE. This was open-label and uncontrolled (no placebo/control group).
Randomized, double-blind, placebo-controlled trial in 105 patients with atopic dermatitis receiving PLE vs placebo.
105 atopic dermatitis patients.
PLE modestly improved atopic dermatitis severity vs placebo. Note: atopic dermatitis is primarily managed with topical emollients, corticosteroids, calcineurin inhibitors (tacrolimus, pimecrolimus), and now JAK inhibitors and biologics (dupilumab) — strong evidence-based therapy. PLE adjunctive at most.
Randomized, double-blind, placebo-controlled trial in 50 patients with vitiligo receiving narrow-band UVB phototherapy + PLE vs placebo.
50 vitiligo patients.
PLE adjunct to NB-UVB modestly improved repigmentation vs UVB alone. Niche application; vitiligo treatment requires dermatology specialist care.
Randomized intraindividual trial in 50 healthy volunteers (phototypes I-III) comparing oral nicotinamide with oral Polypodium leucotomos extract before UVA exposure. Outcomes: UVA-induced thymidine dimers (skin and urine) and minimal erythema dose (Faisal et al., Photochem Photobiol Sci 2026).
Healthy volunteers.
Both nicotinamide and PLE raised the minimal erythema dose by about 26%, but neither significantly reduced UVA-induced thymidine dimers in skin or urine — a negative result for UVA-induced DNA-lesion prevention. There was no placebo arm; the comparison was between the two agents.
Observational cohort study in 57 patients with idiopathic photodermatoses (53 polymorphic light eruption, 4 solar urticaria) receiving oral Polypodium leucotomos extract (Caccialanza et al., G Ital Dermatol Venereol 2011).
57 idiopathic photodermatosis patients.
PLE modestly improved photoprotection in this niche population. Open-label/uncontrolled — lower evidence quality.